Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VDJ001 in idiopathic multicentric Castleman disease
ChiCTR2200058864Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of VDJ-001 in idiopathic multicentric Castleman disease (iMCD), sponsored by Peking Union Medical College Hospital. Primary endpoints: Pharmacokinetics of VDJ001 and Safety and tolerability of VDJ001. Planned start May 2022; status: not yet recruiting.
02
Drugs
VDJ-001
03
Conditions
idiopathic multicentric Castleman disease (iMCD)
Beyond the preview
Go deeper on ChiCTR2200058864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058864.